CD63 and neoplasm: These novel findings further provided molecular insight into TIMP-1-mediated chemotherapy resistance involving glycolytic tumor metabolism and extracellular acidosis in addition to the previously characterized CD63/integrinβ1/FAK/PI3K/ERKs survival signaling pathways [12,13,14,18,59].